Antibodies detected in samples from 21,730 pregnant women

Immunohematology

Volumn 19, Issue 3, 2003, Pages 89-92

  Jovanovic Srzentic, Snezana ^a   Djokic, Milan ^a   Tijanic, Nenad ^a   Djordjevic, Radmila ^a   Rizvan, Nada ^a   Plecas, Darko ^b   Filimonovic, Dejan ^c  

^a National Blood Transfusion Institute   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Fetomaternal hemorrhage; Non anti D antibodies; Pregnancy; Screening; Third trimester

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RHESUS D ANTIBODY;

ADULT; ALLOIMMUNIZATION; ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIBODY SPECIFICITY; ARTICLE; BLOOD GROUP RHESUS SYSTEM; BLOOD SAMPLING; FEMALE; FETOMATERNAL TRANSFUSION; HUMAN; IMMUNOPROPHYLAXIS; MAJOR CLINICAL STUDY; PREGNANCY; PRENATAL CARE; PRIORITY JOURNAL; SCREENING TEST; THIRD TRIMESTER PREGNANCY;

EID: 0042887553     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Oxford: Blackwell Scientific Publications, 1997.
2. Tijanic N, Jovanovic-Srzentic S, Djokic M. Importance of laboratory analysis in antenatal testing. Bilt Hematol Transfuz 1996;1:11-3.
3. Slavkovic B, Vavic N, Pajevic M, Paunovic D, Djokic M. Incidence of red cell antibodies during pregnancy. Bilt Hematol Transfuz 1994;2:49-51.
4. Cepulic-Golubic et al. RhD immunoprophylaxis in pregnancy. Zagreb: Klinickatransfuziologija, 2000.
5. Muhlbacher A, Michl U. Prevalence rate of red blood cell antibodies during gravidity in the Federal province Salzburg. Infusionsther Transfusionsmed 1999;26:348-52.
6. Filbey D, Hanson U, Wesstrom G. The prevalence of red cell antibodies correlated to the outcome of the newborn. A 12 year study in central Sweden. Acta Obstet Gynecol Scand 1995;74:687-92.
7. Brecker M, ed. Technical manual. 14th ed. Bethesda, MD: American Association of Blood Banks, 2003.
8. Judd WJ, Luban NLC, Ness PM, et al. Prenatal and perinatal immunohematology: recommendations for serologic management of the fetus, newborn infant, and obstetric patient. Transfusion 1990;30:175-83.
9. Contreras M, Garners SF. Laboratory procedures for the prediction of the severity of haemolytic disease of the newborn. Vox Sang 1995;59-63.
10. Garratty G. Laboratory procedures for the prediction of the severity of haemolytic disease of the newborn, Vox Sang 1995;64-9.
11. Daniels G. Human blood groups. Oxford: Blackwell Science, 1995.
12. Zupanska B. Clinical significance of alloantibodies. In: red cell immunohaematology. Proceedings of the European School of Transfusion Medicine 1998;59-66.
13. Bowell PJ, Inskip MJ, Jones MN. The significance of anti-C alloimmunization in pregnancy. Clin Lab Haematol 1988;10:251-5.
14. Cheepsattayacorn R, Fongsatitkul L, Chotinaruemol S, et al. Anti-E as a cause of hemolytic disease of the newborn. J Med Assoc Thai 1997; Sep. 80(Suppl 1).
15. Bowell PJ, Brown SE, Dike AE, et al. The significance of anti-c alloimmunization in pregnancy. Br J Obstet Gynaecol 1986;93:1044-8.
16. Lin SV, Lin DT, Hisieh SW, et al. Hemolytic disease of the newborn caused by anti-M antibody. J Formos Med Assoc 1996;95:390-2.
17. De Yong-Owens, Kennedy M, Rose RL, et al. Anti-M isoimmunization management and outcome at the Ohio State University from 1969 to 1995. Obstet Gynecol 1997;90:962-6.
18. Hadley AG. A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn. Vox Sang 1998;74(Suppl 2):375-83.
19. Moise KJ Jr. Non-anti-D antibodies in red cell alloimmunization. Eur J Obstet Gynecol Reprod Biol 2000;Sep; 92(1):75-81.
20. Judd WJ. Practice guidelines for prenatal and perinatal immunohematology, revisited. Transfusion 2001;41:1445-52.